GBI Research, Dec 2009, Pages: 81
for the respiratory diseases therapeutics market from 2000 to 2008, forecast forward to 2015
- Analysis of the leading therapeutic segments including asthma, chronic obstructive pulmonary disease (COPD), pulmonary
Frost & Sullivan, March 2011, Pages: 91
technologies. In this research, Frost & Sullivan's expert analysts thoroughly examine the residential, commercial, and industrial end-user segments.
This analysis is available through our Technical Insights
Datamonitor, Dec 2010, Pages: 182
market potential and growth opportunities. In particular, regulations in the emerging markets play a considerable role in the availability and spectrum of COPD treatments compared to the US.
Scope
-Insight
Datamonitor, July 2010, Pages: 75
Prescription pharmaceutical sales and growth rate performance, 2002-14
Financial performance, 2002-14
Nycomed: PharmaVitae forecasts at a glance
Strategic insight
Historical growth led by Altana acquisition
Takeda Pacific, Sep 2006, Pages: 163
This research study is about drug delivery systems. It provides readers with relevant information, insights and analysis. This important medical opportunity is assessed in terms of technical
GBI Research, Nov 2011, Pages: 143
in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing” which provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most
GlobalData, Sep 2011, Pages: 41
and services pertaining to asthma management and care. The company markets its flagship products under the brand name of Niox. The company markets two products globally NIOX Flex and NIOX MINO. The company
GlobalData, Sep 2010, Pages: 26
Cobalis Corp. (Cobalis) is a specialty pharmaceutical company engaged in the developing and commercializing pharmaceutical products for allergic diseases. The company has one product Pre
Merchant Research and Consulting Ltd., July 2011, Pages: 71
’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
Your company’s business and sales activities will be boosted by gaining an insight
Business Insights, Jan 2008, Pages: 101
and acceptance of these therapies has now been established.
This is largely due to their effectiveness in areas such as HIV and asthma, but the successful positioning of combination products remains difficult
GBI Research, Dec 2009, Pages: 71
provides an insight into government regulations in the US and Europe covering DTC advertisements and their implications for the marketing strategies of the pharmaceutical companies. The study provides
Life Science Intelligence, Inc., Jan 2011
This report includes details on over 300 emerging medical technology companies that: have presented at a 2010 Elsevier/Medtech Insight In3 investor/partnering conference; have presented at a 2010
GBI Research, Feb 2011, Pages: 100
is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The report gives insight about
Markets and Markets, Feb 2011, Pages: 264
delivery technologies.
REASONS FOR DOING THE STUDY:
More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body
Business Insights, May 2008, Pages: 175
Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical
GlobalData, May 2011, Pages: 35
KarmelSonix Ltd. (KSX) - Financial and Strategic SWOT Analysis Review
Summary
KarmelSonix Ltd. (KarmelSonix) is a healthcare company engaged in the research, development and commercialization
GlobalData, Sep 2011, Pages: 39
and commercialization of a novel class of biopharmaceutical products called Immunodrugs, used in the treatment and prevention of respiratory, nervous system, metabolic, cardiovascular and inflammation/autoimmunity
Business Insights, June 2007, Pages: 244
also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.
‘Outlook for RNAi 2007’ is a new report which provides a detailed insight
Life Science Intelligence, Inc., Dec 2009, Pages: 1763
-2009 Elsevier/Medtech Insight In3 investor/partnering conference; or have been identified by LSI's in-house research team from 2004 thru 2009.
Coverage includes innovations in a broad spectrum of medical
GlobalData, Sep 2011, Pages: 22
Cobalis Corporation - Strategic SWOT Analysis Review
Summary
Cobalis Corp. (Cobalis) is a specialty pharmaceutical company engaged in the developing and commercializing pharmaceutical products
